首页>
外国专利>
IMPROVED TARGETED T-CELL THERAPY FOR TREATMENT OF MULTIPLE MYELOMA
IMPROVED TARGETED T-CELL THERAPY FOR TREATMENT OF MULTIPLE MYELOMA
展开▼
机译:改善靶向T细胞疗法治疗多发性骨髓瘤
展开▼
页面导航
摘要
著录项
相似文献
摘要
Provided herein are activated adoptive T-cell compositions targeting plasma cell dyscrasias such as multiple myeloma and methods of treating plasma cell dyscrasias such as multiple myeloma using such compositions. The T-cell compositions of the present disclosure are activated against a select group of antigens associated with multiple myeloma (MMAAs) and, in certain embodiments, in combination with more widely expressed tumor associated antigens (TAAs). In particular, the T-cell compositions of the present disclosure are directed to the MMAAs selected from B-cell maturation antigen (BCMA), X box Protein 1 (XBP1), CS1, and Syndecan-1 (CD 138), or a combination thereof. In certain embodiments, the T-cell composition includes T-cells activated to a TAA selected from preferentially expressed antigen of melanoma (PRAME), Survivin, Wilms' Tumor 1 protein (WT1), and melanoma antigen 3 (MAGE-A3), or a combination thereof.
展开▼